BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Deals

  At $306 Million, Recursion Pharmaceuticals IPO will be Bigger than Expected

  Recursion Pharma is getting bigger and bigger with its new public offering. The Recursion Pharmaceuticals IPO is anticipated to bring approx $306 million.

  April 13, 2021

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  2021 COVID-19 News: Breakthrough Cases, Children’s Viral Load and More

  Please check out the biopharma industry’s COVID-19 stories that are trending for April 13, 2021.

  April 13, 2021

   · 

  4 min read

   · 

  BioSpace Editorial Staff
• 

  Business

  Lilly Closes Dermira’s Menlo Park Facility, Cutting 163 Jobs in the Process

  Eli Lilly and Company is set to cut 163 jobs as it closes its Dermira facility in Menlo Park and sells off the latter company’s sweat drug Qbrexza, which is being snatched up by Journey Medical.

  April 13, 2021

   · 

  3 min read

   · 

  Brandon May
• 

  BioMidwest

  Four Biopharma Companies Raise Hundreds of Millions in Series B Rounds

  This morning, multiple companies announced hundreds of millions of dollars were raised in Series B rounds that will be used to advance therapeutics and business development programs.

  April 13, 2021

   · 

  4 min read

   · 

  Alex Keown
• 

  FDA

  Genentech and Novartis Win FDA Approval for Self-Injectable Form of Xolair

  The U.S. Food and Drug Administration (FDA) approved a prefilled syringe for self-injection of an allergic diseases treatment developed by Novartis and Genentech, a Roche company.

  April 13, 2021

   · 

  2 min read

   · 

  Alex Keown
• 

  BioCapital

  Arcellx Raises $115 Million Series C to Advance Next-Generation CAR-T Therapies

  Arcellx, based in Gaithersburg, Maryland, closed on a Series C financing round worth $115 million.

  April 13, 2021

   · 

  3 min read

   · 

  Mark Terry
• 

  FDA

  FDA Grants vTv’s Type 1 Diabetes Drug Breakthrough Therapy Designation

  The U.S. Food and Drug Administration (FDA) granted vTv Therapeutics’ TTP399 Breakthrough Therapy designation for type 1 diabetes. This designation provides companies more support and the possibility of shorter development and review timelines.

  April 13, 2021

   · 

  3 min read

   · 

  Mark Terry
• 

  FDA

  Celularity Gains FDA Orphan Drug Status on Strength of Placental Stem Cell Trials

  On Tuesday, Celularity received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for its off-the-shelf natural killer cell therapy for malignant gliomas.

  April 13, 2021

   · 

  4 min read

   · 

  Gail Dutton
• 

  Business

  Amarin CEO Thero to Retire as Company Pivots Focus to Global Markets

  Amarin announced the forthcoming retirement of President and CEO John Thero, and the elevation of current head of commercial for Europe and senior vice president Karim Mikhail to the top role.

  April 13, 2021

   · 

  2 min read

   · 

  Mark Zipkin
• 

  Policy

  CDC, FDA Recommend Pausing J&J COVID-19 Vaccine Rollout Over Blood Clots

  The U.S. CDC and the U.S. FDA have identified six cases in the U.S. of a “rare and severe” type of blood clot, which seems to be linked to the COVID-19 vaccine by Johnson & Johnson.

  April 13, 2021

   · 

  5 min read

   · 

  Mark Terry